News
Public · Published
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
China Medical System Holdings said its subsidiary Rxilient Medical received Singapore approval on 3 November 2026 for ruxolitinib phosphate cream, sold as Lumirix. The approval covers non-segmental vitiligo with facial involvement in adults and adolescents aged 12 and older.
Published:
Updated:
What happened
China Medical System Holdings said its subsidiary Rxilient Medical received Singapore approval on 3 November 2026 for ruxolitinib phosphate cream, sold as Lumirix. The approval covers non-segmental vitiligo with facial involvement in adults and adolescents aged 12 and older.
Confirmed
Global impact / market context
Approval gives CMS a regulatory route to sell Lumirix in Singapore for the specified patients, potentially adding sales to its existing business in Hong Kong, Macau and Taiwan. Actual revenue will depend on launch timing, prescribing, patient uptake and the company’s ability to supply the cream.
Analyst inference
The article calls Lumirix Singapore’s first and only topical prescription drug directly targeting vitiligo’s disease mechanism, and says it addresses an unmet treatment need. CMS says sales have already launched in Hong Kong, Macau and Taiwan, placing Singapore alongside those markets.
Confirmed
What to watch
- Watch for Singapore launch timing and availability; approval alone does not show when patients can obtain the cream or when sales could begin. Analyst inference
- Track prescribing and patient uptake among eligible adults and adolescents, because adoption will determine whether the approval translates into meaningful Singapore revenue. Analyst inference
- Look for updates on commercial availability and sales in Singapore, which would show whether the new approval is contributing to CMS’s regional business. Analyst inference
Evidence
- Original source link unavailable